{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955534",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955534_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"antacids\" outputclass=\"int-drug\">antacids</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dolutegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34479\">dolutegravir</xref></ph> should be taken 2 hours before or 6 hours after antacids</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   antacids   decrease   the exposure to   oral   dolutegravir .  Manufacturer advises  dolutegravir  should be taken 2 hours before or 6 hours after antacids .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Antacids</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955535",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955535_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"apalutamide\" outputclass=\"int-drug\">Apalutamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Apalutamide   is predicted to   decrease   the exposure to   dolutegravir .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Apalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955536",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955536_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"atazanavir\" outputclass=\"int-drug\">Atazanavir</ph> <ph outputclass=\"int-substanceQualifier\">(alone or boosted with ritonavir)</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose—consult product literature</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Atazanavir   (alone or boosted with ritonavir)   slightly   increases   the exposure to   dolutegravir .  Manufacturer advises adjust dose—consult product literature .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atazanavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955537",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955537_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"bosentan\" outputclass=\"int-drug\">Bosentan</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Bosentan   is predicted to   decrease   the exposure to   dolutegravir .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Bosentan</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955538",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955538_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium acetate\" outputclass=\"int-drug\">calcium acetate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dolutegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34479\">dolutegravir</xref></ph> should be taken 2 hours before or 6 hours after <ph otherprops=\"calcium acetate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/calcium-acetate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP104228\">calcium acetate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium acetate   decreases   the absorption of   dolutegravir .  Manufacturer advises  dolutegravir  should be taken 2 hours before or 6 hours after  calcium acetate .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Calcium acetate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955539",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955539_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium carbonate\" outputclass=\"int-drug\">calcium carbonate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dolutegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34479\">dolutegravir</xref></ph> should be taken 2 hours before or 6 hours after <ph otherprops=\"calcium carbonate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/calcium-carbonate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP93602\">calcium carbonate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium carbonate   decreases   the absorption of   dolutegravir .  Manufacturer advises  dolutegravir  should be taken 2 hours before or 6 hours after  calcium carbonate .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Calcium carbonate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955540",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955540_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium chloride\" outputclass=\"int-drug\">calcium chloride</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dolutegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34479\">dolutegravir</xref></ph> should be taken 2 hours before or 6 hours after <ph otherprops=\"calcium chloride\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/calcium-chloride.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP93603\">calcium chloride</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium chloride   decreases   the absorption of   dolutegravir .  Manufacturer advises  dolutegravir  should be taken 2 hours before or 6 hours after  calcium chloride .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Calcium chloride</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955541",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955541_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium gluconate\" outputclass=\"int-drug\">calcium gluconate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dolutegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34479\">dolutegravir</xref></ph> should be taken 2 hours before or 6 hours after <ph otherprops=\"calcium gluconate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/calcium-gluconate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP93600\">calcium gluconate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium gluconate   decreases   the absorption of   dolutegravir .  Manufacturer advises  dolutegravir  should be taken 2 hours before or 6 hours after  calcium gluconate .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Calcium gluconate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955542",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955542_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium lactate\" outputclass=\"int-drug\">calcium lactate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dolutegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34479\">dolutegravir</xref></ph> should be taken 2 hours before or 6 hours after <ph otherprops=\"calcium lactate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/calcium-lactate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP93601\">calcium lactate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium lactate   decreases   the absorption of   dolutegravir .  Manufacturer advises  dolutegravir  should be taken 2 hours before or 6 hours after  calcium lactate .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Calcium lactate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955543",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955543_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"calcium phosphate\" outputclass=\"int-drug\">calcium phosphate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dolutegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34479\">dolutegravir</xref></ph> should be taken 2 hours before or 6 hours after <ph otherprops=\"calcium phosphate\" outputclass=\"int-drug\"><xref format=\"dita\" href=\"drug/calcium-phosphate.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP107980\">calcium phosphate</xref></ph></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   calcium phosphate   decreases   the absorption of   dolutegravir .  Manufacturer advises  dolutegravir  should be taken 2 hours before or 6 hours after  calcium phosphate .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Calcium phosphate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955544",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955544_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">Carbamazepine</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dolutegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34479\">dolutegravir</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Carbamazepine   decreases   the exposure to   dolutegravir .  Manufacturer advises adjust  dolutegravir  dose .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955545",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955545_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dabrafenib\" outputclass=\"int-drug\">Dabrafenib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dabrafenib   is predicted to   decrease   the exposure to   dolutegravir .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Dabrafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955546",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955546_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"efavirenz\" outputclass=\"int-drug\">Efavirenz</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dolutegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34479\">dolutegravir</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Efavirenz   moderately   decreases   the exposure to   dolutegravir .  Manufacturer advises adjust  dolutegravir  dose .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Efavirenz</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955547",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955547_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"encorafenib\" outputclass=\"int-drug\">Encorafenib</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Encorafenib   is predicted to   increase   the exposure to   dolutegravir .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Encorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955548",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955548_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"enzalutamide\" outputclass=\"int-drug\">Enzalutamide</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Enzalutamide   is predicted to   decrease   the exposure to   dolutegravir .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Enzalutamide</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955549",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955549_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"etravirine\" outputclass=\"int-drug\">Etravirine</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dolutegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34479\">dolutegravir</xref></ph> dose unless given with atazanavir, darunavir, or lopinavir (all boosted with ritonavir)</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Etravirine   moderately   decreases   the exposure to   dolutegravir .  Manufacturer advises adjust  dolutegravir  dose unless given with atazanavir, darunavir, or lopinavir (all boosted with ritonavir) .    \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etravirine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955550",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955550_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">Dolutegravir</ph> <ph outputclass=\"int-effectQualifier\">might</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the concentration of</ph> <ph otherprops=\"fampridine\" outputclass=\"int-drug\">fampridine</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Dolutegravir   might   increase   the concentration of   fampridine .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fampridine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955551",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955551_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fosamprenavir\" outputclass=\"int-drug\">Fosamprenavir</ph> <ph outputclass=\"int-substanceQualifier\">boosted with ritonavir</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid if resistant to HIV-integrase inhibitors</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fosamprenavir   boosted with ritonavir   slightly   decreases   the exposure to   dolutegravir .  Manufacturer advises avoid if resistant to HIV-integrase inhibitors .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosamprenavir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955552",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955552_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"fosphenytoin\" outputclass=\"int-drug\">Fosphenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dolutegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34479\">dolutegravir</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Fosphenytoin   is predicted to   decrease   the exposure to   dolutegravir .  Manufacturer advises adjust  dolutegravir  dose .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosphenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955553",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955553_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph outputclass=\"int-route\">Oral</ph> <ph otherprops=\"iron\" outputclass=\"int-drug\">iron</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph outputclass=\"int-route\">oral</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dolutegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34479\">dolutegravir</xref></ph> should be taken 2 hours before or 6 hours after iron</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Oral   iron   decreases   the absorption of   oral   dolutegravir .  Manufacturer advises  dolutegravir  should be taken 2 hours before or 6 hours after iron .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Iron</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955554",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955554_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">Dolutegravir</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"metformin\" outputclass=\"int-drug\">metformin</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dolutegravir   increases   the exposure to   metformin .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Metformin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955555",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955555_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"mitotane\" outputclass=\"int-drug\">Mitotane</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Mitotane   is predicted to   decrease   the exposure to   dolutegravir .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "22",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Mitotane</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955556",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955556_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"nevirapine\" outputclass=\"int-drug\">Nevirapine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dolutegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34479\">dolutegravir</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Nevirapine   is predicted to   decrease   the exposure to   dolutegravir .  Manufacturer advises adjust  dolutegravir  dose .    \n\n"
						}
					],
					"hasOrder": "23",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Nevirapine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955557",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955557_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"oxcarbazepine\" outputclass=\"int-drug\">Oxcarbazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dolutegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34479\">dolutegravir</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Oxcarbazepine   is predicted to   decrease   the exposure to   dolutegravir .  Manufacturer advises adjust  dolutegravir  dose .    \n\n"
						}
					],
					"hasOrder": "24",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Oxcarbazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955558",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955558_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenobarbital\" outputclass=\"int-drug\">Phenobarbital</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dolutegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34479\">dolutegravir</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenobarbital   is predicted to   decrease   the exposure to   dolutegravir .  Manufacturer advises adjust  dolutegravir  dose .    \n\n"
						}
					],
					"hasOrder": "25",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenobarbital</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955559",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955559_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"phenytoin\" outputclass=\"int-drug\">Phenytoin</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dolutegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34479\">dolutegravir</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Phenytoin   is predicted to   decrease   the exposure to   dolutegravir .  Manufacturer advises adjust  dolutegravir  dose .    \n\n"
						}
					],
					"hasOrder": "26",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955560",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955560_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">Dolutegravir</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">increase</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pramipexole\" outputclass=\"int-drug\">pramipexole</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Dolutegravir   is predicted to   increase   the exposure to   pramipexole .  Manufacturer advises adjust dose .    \n\n"
						}
					],
					"hasOrder": "27",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pramipexole</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955561",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955561_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"primidone\" outputclass=\"int-drug\">Primidone</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dolutegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34479\">dolutegravir</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Primidone   is predicted to   decrease   the exposure to   dolutegravir .  Manufacturer advises adjust  dolutegravir  dose .    \n\n"
						}
					],
					"hasOrder": "28",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Primidone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955562",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955562_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"rifampicin\" outputclass=\"int-drug\">Rifampicin</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dolutegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34479\">dolutegravir</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Rifampicin   moderately   decreases   the exposure to   dolutegravir .  Manufacturer advises adjust  dolutegravir  dose .    \n\n"
						}
					],
					"hasOrder": "29",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rifampicin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955563",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955563_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"St John's wort\" outputclass=\"int-drug\">St John's wort</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dolutegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34479\">dolutegravir</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "St John's wort   is predicted to   decrease   the exposure to   dolutegravir .  Manufacturer advises adjust  dolutegravir  dose .    \n\n"
						}
					],
					"hasOrder": "30",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>St John's wort</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955564",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955564_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"sucralfate\" outputclass=\"int-drug\">Sucralfate</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the absorption of</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Sucralfate   decreases   the absorption of   dolutegravir .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "31",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sucralfate</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955565",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2#bnf_i1643857955565_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"tipranavir\" outputclass=\"int-drug\">Tipranavir</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\">dolutegravir</ph>. <ph outputclass=\"int-action\">Manufacturer advises adjust <ph otherprops=\"dolutegravir\" outputclass=\"int-heading-drug\"><xref format=\"dita\" href=\"drug/dolutegravir.xml\" type=\"interaction\" rel=\"drug\" bnfid=\"PHP34479\">dolutegravir</xref></ph> dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Tipranavir   moderately   decreases   the exposure to   dolutegravir .  Manufacturer advises adjust  dolutegravir  dose .    \n\n"
						}
					],
					"hasOrder": "32",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Tipranavir</title>"
					}
				}
			],
			"hasSearchLabel": " Dolutegravir  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/dolutegravir-2.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Dolutegravir </title>"
			},
			"rdfs:label": "dolutegravir"
		}
	]
}